Amendment: SEC Form SC 13G/A filed by CONMED Corporation

11/13/24 4:22:22 PM ET

Biotechnology: Electromedical & Electrotherapeutic Apparatus

Health Care

Get the next $CNMD alert in real time by email

SC 13G/A 1 cnmd13g6th0924.txt CONMED CORPORATION - 09/30/2024 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No._6_) CONMED CORPORATION ------------------------------------------------------------------------------- (Name of Issuer) Common Stock ------------------------------------------------------------------------------- (Title of Class of Securities) 207410101 ------------------------------ (CUSIP Number) 09/30/2024 ------------------------------------------------------------------------------- (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) CUSIP NO. 207410101 --------- ------------------------------------------------------------------------------- 1 NAMES OF REPORTING PERSONS. I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY). EARNEST Partners, LLC ------------------------------------------------------------------------------- 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a) [ ] (b) [ ] ------------------------------------------------------------------------------- 3 SEC USE ONLY ------------------------------------------------------------------------------- 4 CITIZENSHIP OR PLACE OF ORGANIZATION Delaware ------------------------------------------------------------------------------- 5 SOLE VOTING POWER 1,867,201 NUMBER OF ----------------------------------------------------------------- SHARES BENEFICIALLY 6 SHARED VOTING POWER 417,606 OWNED BY ----------------------------------------------------------------- EACH REPORTING 7 SOLE DISPOSITIVE POWER 2,784,300 PERSON WITH ----------------------------------------------------------------- 8 SHARED DISPOSITIVE POWER 0 ------------------------------------------------------------------------------- 9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 2,784,300 ------------------------------------------------------------------------------- 10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)[ ] ------------------------------------------------------------------------------- 11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 9.0% ------------------------------------------------------------------------------- 12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) ------------------------------------------------------------------------------- IA ------------------------------------------------------------------------------- ------------------------------------------------------------------------------- ------------------------------------------------------------------------------- ------------------------------------------------------------------------------- ------------------------------------------------------------------------------- Item 1 (a) Name of Issuer CONMED CORPORATION (b) Address of Issuer's Principal Executive Offices 11311 Concept Boulevard, Largo, Florida 33773 Item 2 (a) Name of Person Filing EARNEST Partners, LLC (b) Address of Principal Business Office or, if none, Residence 1180 Peachtree Street NE, Suite 2300, Atlanta, Georgia 30309 (c) Citizenship Delaware (d) Title of Class of Securities Common Stock (e) CUSIP Number 207410101 Item 3. If this statement is filed pursuant to 13d-1(b) or 13d-2(b) or (c), check whether the person filing is a: (a) [ ] Broker or dealer registered under section 15 of the Act (b) [ ] Bank as defined in section 3(a)(6) of the Act (c) [ ] Insurance company as defined in section 3(a)(19) of the Act (d) [ ] Investment company registered under section 8 of the Investment Company Act of 1940 (e) [X] An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E); (f) [ ] An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F); (g) [ ] A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G); (h) [ ] A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); (i) [ ] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (j) [ ] Group, in accordance with Rule 13d-1(b)(1)(ii)(J). Item 4. Ownership. Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1. (a) Amount beneficially owned: 2,784,300 (b) Percent of class: 9.0% (c) Number of shares as to which the person has: (i) Sole power to vote or to direct the vote 1,867,201 (ii) Shared power to vote or to direct the vote 417,606 (iii) Sole power to dispose or to direct the disposition of 2,784,300 (iv) Shared power to dispose or to direct the disposition of 0 Item 5. Ownership of Five Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: [ ] Item 6. Ownership of More than Five Percent on Behalf of Another Person. EARNEST Partners, LLC is filing as an investment adviser in accordance with 240.13d-1(b)(1)(ii)(E). No client interest relates to more than five percent of the class. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company. Not Applicable Item 8. Identification and Classification of Members of the Group. Not Applicable Item 9. Notice of Dissolution of a Group Not Applicable Item 10. Certification (a) The following certification shall be included if the statement is filed pursuant to Rule 13d-1(b): By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. (b) The following certification shall be included if the statement is filed pursuant to Rule 13d-1(c): By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. November 12, 2024 ---------------------------------- Date /s/ James M. Wilson ---------------------------------- Signature James M. Wilson Chief Compliance Officer ---------------------------------- Name/Title Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001) ACN/Form 13G (C) 2006: Advisor Consultant Network, Inc.

Get the next $CNMD alert in real time by email

Recent Analyst Ratings for

$CNMD

Date	Price Target	Rating	Analyst
6/12/2025		Buy → Hold	Needham
4/28/2025	$55.00	Buy → Hold	Stifel
2/6/2025	$85.00 → $70.00	Overweight → Neutral	Analyst
2/1/2024	$119.00 → $129.00	Buy	Needham
5/22/2023	$140.00	Buy	CL King
3/27/2023	$124.00	Sector Weight → Overweight	KeyBanc Capital Markets
3/21/2023	$96.00	Equal Weight	Wells Fargo
10/12/2022	$85.00	Hold	Jefferies

More analyst ratings

Amendment: SEC Form SC 13G/A filed by CONMED Corporation

11/13/24 4:22:22 PM ET

$CNMD

Biotechnology: Electromedical & Electrotherapeutic Apparatus

Health Care

Get the next $CNMD alert in real time by email

Recent Analyst Ratings for

$CNMD

Date	Price Target	Rating	Analyst
6/12/2025		Buy → Hold	Needham
4/28/2025	$55.00	Buy → Hold	Stifel
2/6/2025	$85.00 → $70.00	Overweight → Neutral	Analyst
2/1/2024	$119.00 → $129.00	Buy	Needham
5/22/2023	$140.00	Buy	CL King
3/27/2023	$124.00	Sector Weight → Overweight	KeyBanc Capital Markets
3/21/2023	$96.00	Equal Weight	Wells Fargo
10/12/2022	$85.00	Hold	Jefferies

More analyst ratings

Amendment: SEC Form SC 13G/A filed by CONMED Corporation

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$CNMD

Amendment: SEC Form SC 13G/A filed by CONMED Corporation

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$CNMD

$CNMD
Insider Purchases

Bronson David M bought $97,322 worth of shares (1,350 units at $72.09), increasing direct ownership by 9% to 16,460 units (SEC Form 4)

Schwarzentraub Barbara J bought $99,873 worth of shares (1,442 units at $69.26) (SEC Form 4)

Aronson Martha Goldberg bought $141,960 worth of shares (2,000 units at $70.98) (SEC Form 4)

$CNMD
Insider Trading

Lalomia Brent acquired $1,284 worth of shares (32 units at $40.60) (SEC Form 5)

Chief Information Officer Glaze Richard sold $10,591 worth of shares (257 units at $41.21), closing all direct ownership in the company (SEC Form 4)

Chief Information Officer Glaze Richard converted options into 375 shares and covered exercise/tax liability with 118 shares (SEC Form 4)

$CNMD
Press Releases

CONMED Corporation Announces Chief Financial Officer Transition

CONMED Corporation to Present at the 44th Annual J.P. Morgan Healthcare Conference

CONMED Corporation to Announce Fourth Quarter 2025 Financial Results on January 28, 2026

$CNMD
SEC Filings

CONMED Corporation filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

CONMED Corporation filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

SEC Form 144 filed by CONMED Corporation

$CNMD
Analyst Ratings

CONMED downgraded by Needham

CONMED downgraded by Stifel with a new price target

CONMED downgraded by Analyst with a new price target

$CNMD
Financials

CONMED Corporation to Announce Fourth Quarter 2025 Financial Results on January 28, 2026

CONMED Corporation Announces Third Quarter 2025 Financial Results

CONMED Corporation to Announce Third Quarter 2025 Financial Results on November 5, 2025

$CNMD
Leadership Updates

CONMED Corporation Appoints LaVerne Council as Chair of the Board of Directors

Beta Bionics Announces the Appointment of Martha Goldberg Aronson as Chair of Its Board of Directors

$CNMD
Large Ownership Changes